This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 2 December 2020.

For the Commission

The President

Ursula VON DER LEYEN

( 1 ) OJ L 327, 11.12.2015, p. 1 .

( 2 ) Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods ( OJ L 351, 30.12.2017, p. 72 ).

( 3 ) Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements ( OJ L 183, 12.7.2002, p. 51 ).

( 4 ) EFSA Journal 2020;18(5):6099.

( 5 ) Pasics Szakonyiné I, 2011 (unpublished study report). Repeated dose 28-day oral gavage toxicity study with AstraGinTM in rats. Study No: 413.407.3084. Toxi-Coop Zrt., Hungary.

( 6 ) Zin HM, 2016 (unpublished study report). Bacterial reverse mutation test (Ames test) for AstraGinTM. Study code: GLP/J165/2016/48). Environmental Technology Research Centre (ETRC). Shah Alam, Selangor, Malaysia.

( 7 ) Upadhyaya S and Wang R, 2017 (unpublished study report). 90-days repeated dose oral toxicity study of Astragin® in Wistar rats. 161101/NVS/PC. July 2017. 319pp. Vedic Life Sciences Pvt, Ltd. Mumbai, India.

( 8 ) Vedic Lifesciences, 2019a (unpublished study report). Panax notoginseng proprietary extract: in vitro micronucleus test in CHO-K1 cells. Study Nr. 190503/NL/PC. Mumbai, India.

( 9 ) Vedic Lifesciences, 2019b (unpublished study report). Astragalus membranaceus extract: in vitro micronucleus test in CHO-K1 cells. Study Nr. 190502/NL/PC. Mumbai, India.

COMMISSION IMPLEMENTING REGULATION (EU) 2020/1821 of 2 December 2020 authorising the placing on the market of an extract from ANNEX